Benitec Biopharma Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Benitec Biopharma wird ein Gewinn- und Umsatzwachstum von 24.9% bzw. 75.5% pro Jahr prognostiziert, während der Gewinn pro Aktie um 21% pro Jahr wachsen soll.

Wichtige Informationen

24.9%

Wachstumsrate der Gewinne

21.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	75.5%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	18 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Companies Like Benitec Biopharma (NASDAQ:BNTC) Are In A Position To Invest In Growth

Oct 02

Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable

Nov 30

We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully

Sep 30

Will Benitec Biopharma (NASDAQ:BNTC) Spend Its Cash Wisely?

May 12

Benitec Bio secures $13M capital via equity offering

Apr 28

Can Benitec Biopharma (NASDAQ:BNTC) Afford To Invest In Growth?

Jan 27

How Does Benitec Biopharma's (NASDAQ:BNTC) CEO Salary Compare to Peers?

Dec 02

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:BNTC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2027	N/A	-61	-10	N/A	3
6/30/2026	N/A	-43	-20	N/A	4
6/30/2025	N/A	-30	-36	N/A	5
9/30/2024	N/A	-21	-20	-19	N/A
6/30/2024	N/A	-22	-20	-19	N/A
3/31/2024	0	-22	-20	-20	N/A
12/31/2023	0	-22	-18	-18	N/A
9/30/2023	0	-21	-19	-19	N/A
6/30/2023	0	-20	-18	-18	N/A
3/31/2023	0	-20	-19	-19	N/A
12/31/2022	0	-19	-18	-18	N/A
9/30/2022	0	-18	-16	-16	N/A
6/30/2022	0	-18	-16	-16	N/A
3/31/2022	0	-17	-16	-16	N/A
12/31/2021	0	-18	-15	-15	N/A
9/30/2021	0	-16	-15	-15	N/A
6/30/2021	0	-14	-13	-13	N/A
3/31/2021	0	-13	-11	-11	N/A
12/31/2020	0	-11	-10	-10	N/A
9/30/2020	0	-10	-10	-9	N/A
6/30/2020	0	-8	-8	-8	N/A
3/31/2020	1	-7	-6	-6	N/A
12/31/2019	1	-6	N/A	N/A	N/A
9/30/2019	7	-2	2	2	N/A
6/30/2019	12	3	4	5	N/A
3/31/2019	12	2	4	4	N/A
12/31/2018	12	2	N/A	N/A	N/A
9/30/2018	8	-3	-3	-3	N/A
6/30/2018	3	-9	N/A	-7	N/A
3/31/2018	4	-9	N/A	-7	N/A
12/31/2017	6	-7	N/A	-5	N/A
9/30/2017	5	-7	N/A	-5	N/A
6/30/2017	9	-4	N/A	-6	N/A
3/31/2017	7	-7	N/A	-6	N/A
12/31/2016	7	-8	N/A	-10	N/A
9/30/2016	7	-12	N/A	-13	N/A
6/30/2016	3	-18	N/A	-15	N/A
3/31/2016	3	-18	N/A	-17	N/A
12/31/2015	2	-16	N/A	-14	N/A
9/30/2015	2	-12	N/A	-10	N/A
6/30/2015	3	-9	N/A	-7	N/A
3/31/2015	3	-6	N/A	-5	N/A
12/31/2014	1	-7	N/A	-7	N/A
9/30/2014	1	-7	N/A	-8	N/A
6/30/2014	1	-7	N/A	-9	N/A
3/31/2014	1	-5	N/A	-8	N/A
12/31/2013	1	-3	N/A	-6	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BNTC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: BNTC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: BNTC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: BNTC wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: BNTC wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von BNTC in 3 Jahren voraussichtlich hoch sein wird

Benitec Biopharma Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Benitec Biopharma Inc., Annual General Meeting, Dec 04, 2024

New major risk - Revenue and earnings growth

Benitec Biopharma Inc. Reports Positive Data from Two Subjects Treated with Low-Dose Bb-301 in Phase 1B/2A Study Presented At 29Th Annual Congress of the World Muscle Society

Benitec Biopharma Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Companies Like Benitec Biopharma (NASDAQ:BNTC) Are In A Position To Invest In Growth

Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-Dose BB-301 in Phase 1b/2a Study

Benitec Biopharma Inc. Announces Appointment of Kishen Mehta to Its Board of Directors

Third quarter 2024 earnings released: US$1.64 loss per share (vs US$2.67 loss in 3Q 2023)

Benitec Biopharma Inc. announced that it has received $40.000019 million in funding from a group of investors

New major risk - Share price stability

Benitec Biopharma Inc. Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study

New minor risk - Share price stability

Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable

Benitec Biopharma Announces First Subject Dosed in Phase 1B/2A Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

New major risk - Financial position

Benitec Biopharma Inc., Annual General Meeting, Dec 06, 2023

Full year 2023 earnings released: US$14.12 loss per share (vs US$37.88 loss in FY 2022)

Benitec Biopharma Regains Compliance with the Bid Price Rule

Benitec Biopharma Provides Nasdaq Compliance Update

New major risk - Share price stability

Insufficient new directors

Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program

Benitec Biopharma Inc., Annual General Meeting, Dec 07, 2022

Benitec Biopharma prices of $18M securities offering

Benitec Biopharma Receives Letter from the Listing Qualifications Department of the Nasdaq Stock Market for Compliance with the Minimum Bid Price Requirement

Full year 2022 earnings: EPS and revenues miss analyst expectations

Benitec GAAP EPS of -$2.23, revenue of $0.07M

Third quarter 2022 earnings released: US$0.40 loss per share (vs US$0.82 loss in 3Q 2021)

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate

First quarter 2022 earnings released: US$0.62 loss per share (vs US$2.45 loss in 1Q 2021)

We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully

Full year 2021 earnings released: US$3.23 loss per share (vs US$8.10 loss in FY 2020)

Benitec Biopharma Inc. Provides Overview of the BB-301 Phase 1B/2A Clinical Trial Design for 2022

Third quarter 2021 earnings released: US$0.82 loss per share (vs US$1.96 loss in 3Q 2020)

Will Benitec Biopharma (NASDAQ:BNTC) Spend Its Cash Wisely?

Benitec Bio secures $13M capital via equity offering

New 90-day low: US$2.59

Benitec Biopharma Inc. Announces the Successful Results of the Interim Analysis of the Bb-301 Pilot Dosing Study

New 90-day high: US$4.71

Can Benitec Biopharma (NASDAQ:BNTC) Afford To Invest In Growth?

New 90-day high: US$3.88

New 90-day high: US$3.34

How Does Benitec Biopharma's (NASDAQ:BNTC) CEO Salary Compare to Peers?

First quarter 2021 earnings released: US$2.45 loss per share

New 90-day low: US$2.76

New 90-day low: US$4.79

Full year earnings released - US$8.10 loss per share

New 90-day low - US$6.68

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken